Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Previous MRI studies reported cortical iron accumulation in early-onset (EOAD) compared to late-onset (LOAD) Alzheimer disease patients.
Why it matters
In postmortem brain tissue, MRI contrast in early-onset and late-onset Alzheimer's was best explained by iron accumulation and changes in cortical myelin rather than by amyloid and tau. This suggests subtypes of Alzheimer's differ in iron and myelin changes that high-field MRI may detect, but it is postmortem tissue analysis with no treatment tested.
-
The present study was aimed to investigate the relationships between thyroid stimulating hormone (TSH), freeT3 (fT3) and freeT4 (fT4) and brain glucose consumption as detectable by means of 2-deoxy-2-(F-18) fluoro-D-glucose (F-18 FDG) Positron Emission Tomography/Computed Tomography (PET/CT) in a selected population with Alzheimer disease (AD).
Why it matters
In 87 people with Alzheimer's disease, thyroid hormone levels within the normal range were related to brain glucose use on PET scans. It explores a possible biological link but does not test any treatment or show that altering thyroid hormones helps.
-
Alzheimer's disease (AD) is a progressive, neurodegenerative brain disorder that attacks neurotransmitters, brain cells, and nerves, affecting brain functions, memory, and behaviors and then finally causing dementia on elderly people.
Why it matters
This study developed a machine learning method to diagnose Alzheimer's disease from structural MRI images. It is about improving diagnosis, not about treating, curing, or preventing the disease.
-
Alzheimer's disease (AD) risk is modified by both genetic and environmental risk factors, which are believed to interact to cooperatively modify pathogenesis.
Why it matters
In this mouse study, a Western diet high in saturated fat and sugars increased amyloid deposits, beta-amyloid burden, and glial activation in mice carrying APOE4 but not in mice carrying APOE3. Because this was done in an animal model, it cannot yet be applied directly to people.
-
Flortaucipir uptake distinguished individuals with PCA and amnestic AD dementia early in the symptomatic course.
Why it matters
In this small study of 5 people with early-stage posterior cortical atrophy, tau-PET binding was higher than in people with early-stage amnestic Alzheimer's disease or controls, and greatest in posterior brain regions. It is a small diagnostic imaging study and does not report any treatment, cure, or prevention of Alzheimer's disease.
-
Mildly demented LBD patients had a significant deficit judging narratives compared to non-demented patients, but this deficit was not correlated with MMSE.
Why it matters
In 56 patients with Lewy body disorders, difficulty organizing narrative speech was linked to Alzheimer's-type pathology rather than overall cognitive score. This is an observational finding about symptoms and does not offer a treatment.
-
Our results suggest that the breakdown of DMN connectivity may occur in the early stage of MCI.
Why it matters
In 130 participants, default mode network functional connectivity was decreased in early mild cognitive impairment compared with cognitively normal subjects and further decreased in late mild cognitive impairment, with no significant gray matter volume differences between groups. This is an imaging observation about network breakdown and does not test any treatment or prevention.
-
Alzheimer's disease (AD) is the most common cause of dementia associated with a progressive neurodegenerative disorder, with a prevalence of 44 million people throughout the world in 2015, and this figure is estimated to double by 2050.
Why it matters
This review describes existing drug treatments for Alzheimer's symptoms and etiology-based approaches, along with lifestyle strategies for prevention such as exercise, mental challenges, socialization, caloric restriction and a healthy diet. It summarizes current knowledge rather than reporting a new treatment or cure.
-
Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer's disease (AD) and these act to control symptoms rather than alter the course of the disease.
Why it matters
This review states that only five treatments are approved for Alzheimer's disease and that these control symptoms rather than change the course of the disease. It notes that disease-modifying therapy is not yet clinically available, though early results from some trials are described as encouraging but requiring caution.
-
Alzheimer's disease (AD) researchers commonly use MRI as a quantitative measure of disease severity.
-
43/100
This article discusses the recent advances in the diagnosis and treatment of Alzheimer disease (AD).
Why it matters
This review covers recent advances in genetics, neuroimaging, clinical diagnosis and staging of Alzheimer disease, including the ability to visualize amyloid pathology in the living brain. It discusses diagnosis and future therapeutic interventions but reports no treatment, cure or prevention.
-
There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-β accumulation or brain atrophy.
Why it matters
This review argues that reduced cerebral blood flow may appear before Alzheimer's symptoms and could serve as a biomarker for the preclinical stage. It is about identifying candidates for future treatment trials, not about a treatment or cure itself.
-
Alzheimer's disease (AD) is a multifactorial disease with genetic (70%) and environmental (30%) causes.
Why it matters
This review describes the genetic factors behind familial and sporadic Alzheimer's disease, including APP, PSEN1, PSEN2, APOE and TREM2. It is a summary of molecular causes and does not report a treatment, cure or prevention.
-
Positron emission tomography (PET) with the glucose analog F-18-fluorodeoxyglucose (FDG) is widely used in the diagnosis of neurodegenerative diseases.
Why it matters
This study optimized the processing pipeline for voxel-based FDG PET testing to predict conversion from mild cognitive impairment to Alzheimer's disease in 108 ADNI subjects. It is a methods study, so it does not treat, cure, or prevent Alzheimer's disease.
-
Saturation and competition binding studies of (3)H-THK5117 in post-mortem AD brain tissue showed the presence of multiple binding sites.
Why it matters
This laboratory study characterized how the tracer THK5117 binds to tau deposits in post-mortem Alzheimer brain tissue. It is early in-vitro work to support future tau PET imaging, not a treatment, cure or prevention.
-
43/100
Oxidative stress and endoplasmic reticulum (ER) stress have been associated with Alzheimer's disease (AD) progression.
Why it matters
In blood immune cells from people with mild cognitive impairment, this lab study found more oxidative stress and an activated form of the cell's antioxidant switch, Nrf2, yet lower levels of the antioxidant enzyme SOD1. It also found signs of stress in the cell's protein-folding machinery (ER stress), both in MCI and in mild Alzheimer's, with related changes in an Alzheimer's mouse model. The authors suggest these may be early markers that "may be followed" in blood, but the study did not test a diagnostic or any treatment.
-
The co-occurrence of both Alzheimer disease (AD) pathology and vascular brain injury (VBI) is very common, especially amongst the oldest of old.
Why it matters
This review reports that Alzheimer disease pathology and vascular brain injury commonly co-occur and contribute additively but independently to dementia risk, and that reducing vascular risk factors may reduce vascular contributions to mixed dementia. It is a review and does not establish a treatment, cure, or prevention.
-
It has been proposed that tau aggregation confined to entorhinal cortex and hippocampus, with no or only minimal Aβ deposition, should be considered as a 'primary age-related tauopathy' (PART) that is not integral to the continuum of sporadic Alzheimer disease (AD).
-
Alzheimer's disease (AD) is the most common form of dementia in the elderly.
-
Accurate assessment of cognitive impairment requires comparison of cognitive performance in individuals to performance in a comparable healthy normative population.
Why it matters
Doctors judge whether someone's memory or thinking test score is "low" by comparing it with healthy people like them, but few reference groups have included many Black older adults or screened out people with hidden brain disease. This study gives age-, race- and education-specific average scores and −1.5 SD cut-points for 8 common tests, based on 320 Black and 392 white ARIC participants aged 61–82 with no clinical or subclinical neurological disease. It is a tool for interpreting test results in people with similar backgrounds; it does not diagnose, treat or prevent Alzheimer's disease.
-
The delayed recall of auditory verbal learning test (AVLT_DR) identified 116 subjects as MCI, resulted in the conversion rate as 44% over the roughly 30-month time interval, missed 7.8% incipient Alzheimer's disease (AD) patients in SCD group who eventually converted to dementia.
Why it matters
In 206 non-demented people from a memory clinic, using delayed recall of the auditory verbal learning test to define mild cognitive impairment gave a 44% conversion rate over about 30 months and missed fewer incipient Alzheimer's cases than a figure memory test. The study is about which memory test best predicts progression, not about treating or preventing the disease.
-
It has long been suggested that prior traumatic brain injury (TBI) increases the subsequent incidence of chronic neurodegenerative disorders, including Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis.
Why it matters
This paper discusses the long-suggested link between prior traumatic brain injury and later chronic neurodegenerative disorders, with the strongest support for an association with Alzheimer's disease. It is a review of associations and does not show that any intervention treats or prevents the disease.
-
We present the first in-human evidence that, in addition to modulating neural circuit activity, DBS may influence the natural course of brain atrophy in a neurodegenerative disease.
-
Strategies to control modifiable risk factors should be implemented to decrease the incidence of AD.
Why it matters
This follow-up of Korean older adults estimated the incidence of Alzheimer's disease and mild cognitive impairment, and found that mild cognitive impairment was associated with a 6-fold increased risk of Alzheimer's disease. It also identified age, lack of formal education, illiteracy, rural residence and marital status as associated with Alzheimer's disease risk.
-
Alzheimer's disease (AD) is the most common form of dementia and has no effective treatment.
Why it matters
This study presents evidence that fibrin deposition increases in the Alzheimer's disease brain and correlates with the degree of neuronal degeneration. It describes a vascular and fibrin-related mechanism but does not report an effective treatment, cure, or prevention.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease
- The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features
- Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease
- Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
- Revealing Individual Neuroanatomical Heterogeneity in Alzheimer Disease Using Neuroanatomical Normative Modeling
- Daytime sleepiness in mild and moderate Alzheimer's disease and its relationship with cognitive impairment
- A benefit-finding intervention for family caregivers of persons with Alzheimer disease: study protocol of a randomized controlled trial
- Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks
- Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease
- C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction With Magnetic Resonance Imaging Markers